:

ANDURIL OPEN TO WEAPONS HUB OUTSIDE US

INDUSTRY DESK1 MIN READ
THU, JUN 11, 2026

■ AI-SUMMARIZED FROM 2 SOURCES ▸ TIMELINE

Anduril Industries CEO Brian Schimpf said the defense-tech startup would "absolutely" consider building its next weapons manufacturing hub outside the United States, citing abundant manufacturing talent in Europe.

Speaking at Founders Forum in the UK, Schimpf indicated the company is willing to explore international locations for future production facilities. The move reflects broader trends in defense manufacturing as companies seek to expand capacity and tap regional expertise. Anduril, valued among the world's most valuable defense-tech startups, currently operates manufacturing operations in the US. The CEO's comments suggest the company is evaluating options to scale production beyond domestic borders. Europe represents a strategic option given existing manufacturing capabilities and defense partnerships across the continent. The statement comes as defense contractors navigate supply chain complexities and increasing demand for weapons systems. No specific timeline or locations have been identified for a potential international hub. The company continues to develop autonomous systems and defense technology for military applications.

■ SOURCES

Bloomberg TechBloomberg Tech

■ SUMMARY WRITTEN BY AI FROM THE LINKS ABOVE

■ MORE FROM THE STARTUPS DESK

Colorado-based biotech startup Enveda, which uses AI to discover new drugs from natural sources, secured $311 million in Series E funding at a $2 billion valuation—double its valuation from a year ago.

3H AGOAI Desk

Modal Labs and Baseten, two platforms enabling businesses to run AI models, are in advanced funding talks that would significantly boost their valuations. The rounds reflect growing investor appetite for AI infrastructure services.

5H AGOAI Desk

Ema, an AI agent platform automating corporate processes in HR, IT, and finance, secured $77 million in Series B funding led by Creaegis. The round brings the startup's total funding to $140 million.

7H AGOAI Desk

Enveda Therapeutics raised $311 million in funding, bringing the AI biotech company's valuation to $2 billion. The capital will accelerate clinical trials for drugs derived from natural compounds.

8H AGOAI Desk

■ SUBSCRIBE TO THE DAILY BRIEF

ONE EMAIL, 5 STORIES, 06:00 UTC. UNSUBSCRIBE ANYTIME.